Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose - The Ponderosa Project

被引：0
|
作者：
Clauss, C. [1 ]
Fabisch, C. [1 ]
Ernst, T. [1 ]
Schenk, T. [1 ]
Saussele, S. [2 ]
Tesch, H. [3 ]
Mayer, J. [4 ]
Hochhaus, A. [1 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany
[2] Univ Med Mannheim, Med Klin 3, Hamatol & Internist Onkol, Mannheim, Germany
[3] Praxis Hamatol & Onkol, Frankfurt, Germany
[4] Ceska leukemicka Spolecnost Pro Zivot, Brno, Czech Republic
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P775
引用
收藏
页码：219 / 219
页数：1
相关论文
共 50 条
  • [41] A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma
    Damian A. Laber
    Roseline I. Okeke
    Carlos Arce-Lara
    Beverly S. Taft
    Cassandra L. Schonard
    Kelly M. McMasters
    Goetz H. Kloecker
    Donald M. Miller
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 611 - 616
  • [42] A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma
    Laber, Damian A.
    Okeke, Roseline I.
    Arce-Lara, Carlos
    Taft, Beverly S.
    Schonard, Cassandra L.
    McMasters, Kelly M.
    Kloecker, Goetz H.
    Miller, Donald M.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (09) : 611 - 616
  • [43] Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome
    Parker, Wendy T.
    Yeoman, Alexandra L.
    Altamura, Haley
    Roberts, Nicola
    Yeung, David T.
    Jamison, Bronte A.
    Field, Chani
    Lustgarten, Stephanie
    Hodgson, Graeme
    Rivera, Victor M.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2013, 122 (21)
  • [44] Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study
    Terabe, Kenya
    Takahashi, Nobunori
    Asai, Shuji
    Hirano, Yuji
    Kanayama, Yasuhide
    Yabe, Yuichiro
    Oguchi, Takeshi
    Fujibayashi, Takayoshi
    Ishikawa, Hisato
    Hanabayashi, Masahiro
    Hattori, Yosuke
    Suzuki, Mochihito
    Kishimoto, Kenji
    Ohashi, Yoshifumi
    Imaizumi, Takahiro
    Imagama, Shiro
    Kojima, Toshihisa
    MODERN RHEUMATOLOGY, 2023, 33 (05) : 891 - 898
  • [45] An observational long-term follow-up study of patients treated with high-dose oral calcitriol
    Alikhani, K.
    Kremenchutzky, M.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S145 - S145
  • [46] A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph plus ) Acute Myeloid Leukemia (AML)
    Senapati, Jayastu
    Ravandi, Farhad
    DiNardo, Courtney D.
    Issa, Ghayas C.
    Sasaki, Koji
    Konopleva, Marina
    Pemmaraju, Naveen
    Chien, Kelly S.
    Ohanian, Maro
    Jabbour, Elias
    Maiti, Abhishek
    Roy, Edith
    Delumpa, Ricardo
    Rivera, Juan
    Loiselle, Christopher
    Banks, Glenda
    Kantarjian, Hagop
    Short, Nicholas
    BLOOD, 2022, 140 : 3880 - 3882
  • [47] Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
    Apperley, Jane F.
    Cortes, Jorge E.
    Jabbour, Elias
    Hochhaus, Andreas
    Hughes, Timothy
    Chuah, Charles
    de Lavallade, Hugues
    Deininger, Michael W.
    Lipton, Jeffrey H.
    Lomaia, Elza
    Maness, Lori
    Mauro, Michael
    McCloskey, James
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rojas, Christine
    Rousselot, Philippe
    Sacha, Tomasz
    Talpaz, Moshe
    Turkina, Anna
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Rosti, Gianantonio
    BLOOD, 2022, 140 : 6760 - 6762
  • [48] CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY
    Paquette, R.
    Mauro, M.
    Simonsson, B.
    Abruzzese, E.
    Andorksy, D.
    Hansen, R.
    Subar, M.
    Turner, M.
    Zyczynski, T.
    Mohamed, H.
    Goldberg, S. L.
    HAEMATOLOGICA, 2015, 100 : 437 - 437
  • [49] Disability Improvement In Early Multiple Sclerosis Patients Treated With Natalizumab In Strive, A Phase 4 Multicenter Observational Study
    Perumal, J.
    Fox, R.
    Balabanov, R.
    Balcer, L.
    Galetta, S.
    Read, P.
    Su, R.
    Xiong, K.
    de Moor, C.
    Campagnolo, D.
    Hotermans, C.
    Lee, L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 41 - 42
  • [50] Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)
    Repp, R.
    Hehlmann, R.
    Linde, H.
    Reiser, M.
    Tesch, H.
    Foreman, A.
    Schreiner, L.
    Hillig, G.
    Oncology Research and Treatment, 2015, 38 : 132 - 132
12345